Inhibition of osteolysis and increase of bone formation after local administration of siRNA-targeting RANK in a polyethylene particle-induced osteolysis model

Acta Biomaterialia

Volumn 13, Issue , 2015, Pages 150-158

  Cordova L A ^a,b,f   Trichet, V ^a,b   Escriou, V ^e   Rosset, P ^a,b,c   Amiaud, J ^a,b   Battaglia, S ^a,b   Charrier, C ^a,b   Berreur, M ^a,b   Brion, R ^a,b,d   Gouin, F ^a,b,d   Layrolle, P ^a,b   Passuti, N ^a,b,d   Heymann, D ^a,b,d  

^a INSERM   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c UNIVERSITÉ DE TOURS   (France)

^d NANTES UNIVERSITY HOSPITAL   (France)

^e CNRS   (France)

^f HOSPITAL SAN BORJA ARRIARÁN   (Chile)

Author keywords

Osteoclast; Polyethylene particle induced osteolysis; siRNA; Wear debris

Indexed keywords

BONE; COMPUTERIZED TOMOGRAPHY; GENE EXPRESSION; MAMMALS; OSTEOBLASTS; PHOSPHATASES; POLYETHYLENES;

BONE FORMATION; NUCLEAR FACTORS; OSTEOCLAST; OSTEOLYSIS; POLYETHYLENE PARTICLE-INDUCED OSTEOLYSIS; POLYETHYLENE PARTICLES; RECEPTOR ACTIVATOR; SIRNA; TARTRATE-RESISTANT ACID PHOSPHATASE; WEAR DEBRIS;

MACROPHAGES;

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; SMALL INTERFERING RNA; ACID PHOSPHATASE; ISOENZYME; LIPOSOME; POLYETHYLENE; TARTRATE-RESISTANT ACID PHOSPHATASE; TNFRSF11A PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MASS; CALVARIA; COMPARATIVE STUDY; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST ACTIVITY; OSTEOCLASTOGENESIS; OSTEOLYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN TARGETING; RNA EXTRACTION; TRABECULAR BONE; ANIMAL; BIOSYNTHESIS; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENE VECTOR; GENETICS; HEK293 CELL LINE; METABOLISM; PATHOLOGY; PHARMACOLOGY; THERAPY;

MUS;

ACID PHOSPHATASE; ANIMALS; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; GENETIC VECTORS; HEK293 CELLS; HUMANS; ISOENZYMES; LIPOSOMES; MICE; OSTEOBLASTS; OSTEOLYSIS; POLYETHYLENE; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RNA, SMALL INTERFERING;

EID: 84920656971     PISSN: 17427061     EISSN: 18787568     Source Type: Journal    
DOI: 10.1016/j.actbio.2014.10.042     Document Type: Article

References (47)

1. E. Ingham, and J. Fisher The role of macrophages in osteolysis of total joint replacement Biomaterials 26 2005 1271 1286 10.1016/j.biomaterials.2004.04.035
2. M. Fukata, A.S. Vamadevan, and M.T. Abreu Toll-like receptors (TLRs) and Nod-like receptors (NLRs) in inflammatory disorders Semin Immunol 21 2009 242 253 10.1016/j.smim.2009.06.005
3. M.S. Caicedo, R. Desai, K. McAllister, A. Reddy, J.J. Jacobs, and N.J. Hallab Soluble and particulate Co-Cr-Mo alloy implant metals activate the inflammasome danger signaling pathway in human macrophages: a novel mechanism for implant debris reactivity J Orthop Res Off Publ Orthop Res Soc 27 2009 847 854 10.1002/jor.20826
4. J.I. Pearl, T. Ma, A.R. Irani, Z. Huang, W.H. Robinson, and R.L. Smith Role of the Toll-like receptor pathway in the recognition of orthopedic implant wear-debris particles Biomaterials 32 2011 5535 5542 10.1016/j.biomaterials.2011.04.046
5. S.B. Goodman Wear particles, periprosthetic osteolysis and the immune system Biomaterials 28 2007 5044 5048 10.1016/j.biomaterials.2007.06.035
6. C.A. Pierre, M. Chan, Y. Iwakura, D.C. Ayers, E.A. Kurt-Jones, and R.W. Finberg Periprosthetic osteolysis: characterizing the innate immune response to titanium wear-particles J Orthop Res 28 2010 1418 1424 10.1002/jor.21149
7. L. Burton, D. Paget, N.B. Binder, K. Bohnert, B.J. Nestor, and T.P. Sculco Orthopedic wear debris mediated inflammatory osteolysis is mediated in part by NALP3 inflammasome activation J Orthop Res Off Publ Orthop Res Soc 31 2013 73 80 10.1002/jor.22190
8. P.E. Purdue, P. Koulouvaris, B.J. Nestor, and T.P. Sculco The central role of wear debris in periprosthetic osteolysis HSS J Musculoskelet J Hosp Spec Surg 2 2006 102 113 10.1007/s11420-006-9003-6
9. T. Lin, Y. Tamaki, J. Pajarinen, H.A. Waters, D.K. Woo, and Z. Yao Chronic inflammation in biomaterial-induced periprosthetic osteolysis: NF-κB as a therapeutic target Acta Biomater 10 2014 1 10 10.1016/j.actbio.2013.09.034
10. J.A. Gasser, P. Ingold, A. Venturiere, V. Shen, and J.R. Green Long-term protective effects of zoledronic acid on cancellous and cortical bone in the ovariectomized rat J Bone Miner Res Off J Am Soc Bone Miner Res 23 2008 544 551 10.1359/jbmr.071207
11. B. Le Goff, E. Soltner, C. Charrier, Y. Maugars, F. Rédini, and D. Heymann A combination of methotrexate and zoledronic acid prevents bone erosions and systemic bone mass loss in collagen induced arthritis Arthritis Res Ther 11 2009 R185 10.1186/ar2877
12. G.A. Odri, S. Dumoucel, G. Picarda, S. Battaglia, F. Lamoureux, and N. Corradini Zoledronic acid as a new adjuvant therapeutic strategy for Ewing's sarcoma patients Cancer Res 70 2010 7610 7619 10.1158/0008-5472.CAN-09-4272
13. G. Moriceau, B. Ory, B. Gobin, F. Verrecchia, F. Gouin, and F. Blanchard Therapeutic approach of primary bone tumours by bisphosphonates Curr Pharm Des 16 2010 2981 2987
14. D.L. Lacey, W.J. Boyle, W.S. Simonet, P.J. Kostenuik, W.C. Dougall, and J.K. Sullivan Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab Nat Rev Drug Discov 11 2012 401 419 10.1038/nrd3705
15. E.S. Orwoll, P.D. Miller, J.D. Adachi, J. Brown, R.A. Adler, and D. Kendler Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study J Bone Miner Res Off J Am Soc Bone Miner Res 25 2010 2239 2250 10.1002/jbmr.119
16. B.Z. Leder, J.N. Tsai, A.V. Uihlein, S.-A.M. Burnett-Bowie, Y. Zhu, and K. Foley Two years of denosumab and teriparatide administration in postmenopausal women with osteoporosis (the DATA Extension Study): a randomized controlled trial J Clin Endocrinol Metab 2014 jc20134440 10.1210/jc.2013-4440
17. S. Téletchéa, V. Stresing, S. Hervouet, M. Baud'huin, M.-F. Heymann, and G. Bertho Novel RANK antagonists for the treatment of bone resorptive disease: theoretical predictions and experimental validation J Bone Miner Res 2014 n/a n/a 10.1002/jbmr.2170
18. L.M. Childs, E.P. Paschalis, L. Xing, W.C. Dougall, D. Anderson, and A.L. Boskey In vivo RANK signaling blockade using the receptor activator of NF-kappaB:Fc effectively prevents and ameliorates wear debris-induced osteolysis via osteoclast depletion without inhibiting osteogenesis J Bone Miner Res Off J Am Soc Bone Miner Res 17 2002 192 199 10.1359/jbmr.2002.17.2.192
19. M. Von Knoch, C. Wedemeyer, A. Pingsmann, F. von Knoch, G. Hilken, and C. Sprecher The decrease of particle-induced osteolysis after a single dose of bisphosphonate Biomaterials 26 2005 1803 1808 10.1016/j.biomaterials.2004.06.010
20. Y. Zeng, O. Lai, B. Shen, J. Yang, Z. Zhou, and P. Kang A systematic review assessing the effectiveness of alendronate in reducing periprosthetic bone loss after cementless primary THA Orthopedics 2011 34 10.3928/01477447-20110228-09
21. S.M. Elbashir, J. Harborth, W. Lendeckel, A. Yalcin, K. Weber, and T. Tuschl Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells Nature 411 2001 494 498 10.1038/35078107
22. T. Sijen, J. Fleenor, F. Simmer, K.L. Thijssen, S. Parrish, and L. Timmons On the role of RNA amplification in dsRNA-triggered gene silencing Cell 107 2001 465 476 10.1016/S0092-8674(01)00576-1
23. L. Gherardini, G. Bardi, M. Gennaro, and T. Pizzorusso Novel siRNA delivery strategy: a new "strand" in CNS translational medicine? Cell Mol Life Sci CMLS 2013 10.1007/s00018-013-1310-8
24. R.S. Bora, D. Gupta, T.K.S. Mukkur, and K.S. Saini RNA interference therapeutics for cancer: challenges and opportunities (review) Mol Med Rep 6 2012 9 15 10.3892/mmr.2012.871
25. Y. Wang, and D.W. Grainger SiRNA Knock-down of RANK signaling to control osteoclast-mediated bone resorption Pharm Res 27 2010 1273 1284 10.1007/s11095-010-0099-5
26. R. Ma, J. Xu, B. Dong, M.D. Kauther, M. Jäger, and C. Wedemeyer Inhibition of osteoclastogenesis by RNA interference targeting RANK BMC Musculoskelet Disord 13 2012 154 10.1186/1471-2474-13-154
27. Y. Wang, K.K. Tran, H. Shen, and D.W. Grainger Selective local delivery of RANK siRNA to bone phagocytes using bone augmentation biomaterials Biomaterials 33 2012 8540 8547 10.1016/j.biomaterials.2012.07.039
28. F. Takeshita Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo Proc Natl Acad Sci 102 2005 12177 12182 10.1073/pnas.0501753102
29. M. Khoury, P. Louis-Plence, V. Escriou, D. Noel, C. Largeau, and C. Cantos Efficient new cationic liposome formulation for systemic delivery of small interfering RNA silencing tumor necrosis factor α in experimental arthritis Arthritis Rheum 54 2006 1867 1877 10.1002/art.21876
30. M. Khoury, V. Escriou, G. Courties, A. Galy, R. Yao, and C. Largeau Efficient suppression of murine arthritis by combined anticytokine small interfering RNA lipoplexes Arthritis Rheum 58 2008 2356 2367 10.1002/art.23660
31. Y. Wang, N.-N. Wu, M. Hu, Y.-Q. Mou, R.-D. Li, and L. Chen Inhibitory effect of adenovirus-mediated siRNA-targeting BMPR-IB on UHMWPE-induced bone destruction in the murine air pouch model Connect Tissue Res 53 2012 528 534 10.3109/03008207.2012.702817
32. J. Rousseau, V. Escriou, F. Lamoureux, R. Brion, J. Chesneau, and S. Battaglia Formulated siRNAs targeting Rankl prevent osteolysis and enhance chemotherapeutic response in osteosarcoma models J Bone Miner Res Off J Am Soc Bone Miner Res 26 2011 2452 2462 10.1002/jbmr.455
33. J.-B. Huang, Y. Ding, D.-S. Huang, W.-K. Zeng, Z.-P. Guan, and M.-L. Zhang RNA Interference targeting p110β reduces tumor necrosis factor-alpha production in cellular response to wear particles in vitro and osteolysis in vivo Inflammation 2013 10.1007/s10753-013-9636-9
34. C. Nich, J. Langlois, A. Marchadier, C. Vidal, M. Cohen-Solal, and H. Petite Oestrogen deficiency modulates particle-induced osteolysis Arthritis Res Ther 13 2011 R100 10.1186/ar3381
35. C. Nich, A. Marchadier, L. Sedel, H. Petite, C. Vidal, and M. Hamadouche Decrease in particle-induced osteolysis in ovariectomized mice J Orthop Res 28 2010 178 183 10.1002/jor.20987
36. H. Rhinn, C. Largeau, P. Bigey, R.L. Kuen, M. Richard, and D. Scherman How to make siRNA lipoplexes efficient? Add a DNA cargo Biochim Biophys Acta 1790 2009 219 230 10.1016/j.bbagen.2009.01.005
37. J. Rousseau, V. Escriou, P. Perrot, G. Picarda, C. Charrier, and D. Scherman Advantages of bioluminescence imaging to follow siRNA or chemotherapeutic treatments in osteosarcoma preclinical models Cancer Gene Ther 17 2010 387 397 10.1038/cgt.2009.89
38. B. Gobin, S. Battaglia, R. Lanel, J. Chesneau, J. Amiaud, and F. Rédini NVP-BEZ235, a dual PI3K/mTOR inhibitor, inhibits osteosarcoma cell proliferation and tumor development in vivo with an improved survival rate Cancer Lett 344 2014 291 298 10.1016/j.canlet.2013.11.017
39. B. Gobin, M.B. Huin, F. Lamoureux, B. Ory, C. Charrier, and R. Lanel BYL719, a new α-specific PI3K inhibitor: single administration and in combination with conventional chemotherapy for the treatment of osteosarcoma Int J Cancer 2014 n/a n/a 10.1002/ijc.29040
40. F. Lamoureux, M. Baud'huin, L. Rodriguez Calleja, C. Jacques, M. Berreur, and F. Rédini Selective inhibition of BET bromodomain epigenetic signalling interferes with the bone-associated tumour vicious cycle Nat Commun 5 2014 10.1038/ncomms4511
41. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002;3:RESEARCH0034.
42. A.J. Rao, E. Gibon, T. Ma, Z. Yao, R.L. Smith, and S.B. Goodman Revision joint replacement, wear particles, and macrophage polarization Acta Biomater 8 2012 2815 2823 10.1016/j.actbio.2012.03.042
43. P. Guihard, Y. Danger, B. Brounais, E. David, R. Brion, and J. Delecrin Induction of osteogenesis in mesenchymal stem cells by activated monocytes/macrophages depends on oncostatin M signaling Stem cells 30 2012 762 772 10.1002/stem.1040
44. V. Nicolaidou, M.M. Wong, A.N. Redpath, A. Ersek, D.F. Baban, and L.M. Williams Monocytes induce STAT3 activation in human mesenchymal stem cells to promote osteoblast formation PLoS ONE 7 2012 e39871 10.1371/journal.pone.0039871
45. H. Yoshida, M. Nishikawa, S. Yasuda, Y. Mizuno, H. Toyota, and T. Kiyota TLR9-dependent systemic interferon-β production by intravenous injection of plasmid DNA/cationic liposome complex in mice J Gene Med 11 2009 708 717 10.1002/jgm.1348
46. Lonez C, Bessodes M, Scherman D, Vandenbranden M, Escriou V, Ruysschaert J-M. Cationic lipid nanocarriers activate Toll-like receptor 2 and NLRP3 inflammasome pathways. Nanomedicine Nanotechnol Biol Med n.d. doi:10.1016/j.nano.2013.12.003.
47. G. Zhang, B. Guo, H. Wu, T. Tang, B.-T. Zhang, and L. Zheng A delivery system targeting bone formation surfaces to facilitate RNAi-based anabolic therapy Nat Med 18 2012 307 314 10.1038/nm.2617